Weekly administration of topotecan–paclitaxel as second-line treatment in ovarian cancer

[1] McGuire WP(1996)Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1-6

[2] Hoskins WJ(2000)Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J Natl Cancer Inst 92 699-708

[3] Brady MF(1998)Chemotherapy of advanced ovarian cancer Semin Oncol 25 340-348

[4] Piccart MJ(1996)Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma J Clin Oncol 14 1552-1557

[5] Bertelsen K(1996)Topotecan an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study J Clin Oncol 12 3056-3061

[6] James K(1997)Topotecan versus paclitaxel for the treatment of recurrent epithelial J Clin Oncol 15 2183-2193

[7] McGuire WP(1998)Topotecan for the treatment of advanced epithelial ovarian cancer: an open label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel J Clin Oncol 16 3345-3352

[8] Ozolos RF(1998)Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study J Clin Oncol 16 2233-2237

[9] Kudelca AP(1997)Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease J Clin Oncol 15 2090-2096

[10] Tresukosol D(1999)Preliminary results of a Cleveland Clinic Cancer Center Gynecologic Oncology Program phase 2 trial of topotecan administered on a 3-day schedule as salvage therapy of platinum and paclitaxel refractory ovarian cancer Proc Am Soc Clin Oncol 18 369a-361

[1] McGuire WP(1996)Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1-6

[2] Hoskins WJ(2000)Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J Natl Cancer Inst 92 699-708

[3] Brady MF(1998)Chemotherapy of advanced ovarian cancer Semin Oncol 25 340-348

[4] Piccart MJ(1996)Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma J Clin Oncol 14 1552-1557

[5] Bertelsen K(1996)Topotecan an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study J Clin Oncol 12 3056-3061

[6] James K(1997)Topotecan versus paclitaxel for the treatment of recurrent epithelial J Clin Oncol 15 2183-2193

[7] McGuire WP(1998)Topotecan for the treatment of advanced epithelial ovarian cancer: an open label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel J Clin Oncol 16 3345-3352

[8] Ozolos RF(1998)Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study J Clin Oncol 16 2233-2237

[9] Kudelca AP(1997)Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease J Clin Oncol 15 2090-2096

[10] Tresukosol D(1999)Preliminary results of a Cleveland Clinic Cancer Center Gynecologic Oncology Program phase 2 trial of topotecan administered on a 3-day schedule as salvage therapy of platinum and paclitaxel refractory ovarian cancer Proc Am Soc Clin Oncol 18 369a-361